Corbus Pharmaceuticals (CRBP) Registration Filing summary

Company overview and business model

• Clinical-stage company developing therapies in oncology and obesity, focusing on innovative approaches to well-understood biological pathways.

• Pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 in cancer, and CRB-913, a CB1 receptor inverse agonist for obesity.

• CRB-701 is in Phase 1/2 trials in the US and Europe, with fast track FDA designations for certain cancers; CRB-913 completed Phase 1a and is in Phase 1b for obesity.

• Former oncology program CRB-601 has been deprioritized after Phase 1 dose escalation.

Financial performance and metrics

• Audited consolidated financial statements for years ended December 31, 2025 and 2024, with an unqualified opinion from EisnerAmper LLP.

• As of March 6, 2026, 17,736,464 shares of common stock were issued and outstanding.

Use of proceeds and capital allocation

• Net proceeds will be used for general corporate purposes, including research, development, clinical trials, acquisitions, working capital, debt reduction, and capital expenditures.

• Pending use, proceeds may be invested in short-term, interest-bearing instruments or investment-grade securities.